Class of severely disabled Medicaid recipients challenged Florida’s decision to deny coverage of a prescription drug, Neurontin, for medically accepted indications that were cited in congressionally-recognized drug compendia, including neuropathic pain and certain psychiatric disorders, in violation of the Medicaid Act.
